High prevalence of p16 staining in malignant tumors.
p16 (CDKN2A) is a member of the INK4 class of cell cycle inhibitors, which is often dysregulated in cancer. However, the prevalence of p16 expression in different cancer types is controversial. 15,783 samples from 124 different tumor types and 76 different normal tissue types were analyzed by immuno...
Saved in:
| Main Authors: | Noémi De Wispelaere, Sebastian Dwertmann Rico, Marcus Bauer, Andreas M Luebke, Martina Kluth, Franziska Büscheck, Claudia Hube-Magg, Doris Höflmayer, Natalia Gorbokon, Sören Weidemann, Katharina Möller, Christoph Fraune, Christian Bernreuther, Ronald Simon, Christian Kähler, Anne Menz, Andrea Hinsch, Frank Jacobsen, Patrick Lebok, Till Clauditz, Guido Sauter, Ria Uhlig, Waldemar Wilczak, Stefan Steurer, Eike Burandt, Rainer Krech, David Dum, Till Krech, Andreas Marx, Sarah Minner |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2022-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0262877&type=printable |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Correction: High prevalence of p16 staining in malignant tumors.
by: Noémi De Wispelaere, et al.
Published: (2025-01-01) -
Prevalence and clinical significance of Claudin-3 expression in cancer: a tissue microarray study on 14,966 tumor samples
by: Seyma Büyücek, et al.
Published: (2024-12-01) -
Reduced occludin expression is related to unfavorable tumor phenotype and poor prognosis in many different tumor types: A tissue microarray study on 16,870 tumors.
by: Seyma Büyücek, et al.
Published: (2025-01-01) -
Glucocorticoid Receptor (GR) Expression in Human Tumors: A Tissue Microarray Study on More than 14,000 Tumors
by: Maria Christina Tsourlakis, et al.
Published: (2025-07-01) -
HMGB1 Deficiency Occurs in a Broad Range of Human Cancers and Is Often Associated with Unfavorable Tumor Phenotype
by: Viktoria Chirico, et al.
Published: (2025-08-01)